Last €0.03 EUR
Change Today +0.002 / 6.45%
Volume 0.0
LHI On Other Exchanges
As of 2:08 AM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

living cell technologies ltd (LHI) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/1/13 - €0.07
52 Week Low
09/2/13 - €0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

living cell technologies ltd (LHI) Related Businessweek News

No Related Businessweek News Found

living cell technologies ltd (LHI) Details

Living Cell Technologies Limited, a cell implant company, develops living cell products for the treatment of diabetes and neurological diseases primarily in New Zealand. The company’s technology, IMMUPEL, coats cells with protective capsules that prevent them from attack by the patient’s immune system. Its product pipeline includes DIABECELL, a porcine insulin-producing cell product for the treatment of type 1 diabetes; and NTCELL, a choroid plexus cell product to treat Parkinson's disease and other disorders, such as stroke, Huntington's disease, and hearing loss, as well as wound hearing. Living Cell Technologies Limited was founded in 1987 and is based in Auckland, New Zealand.

Founded in 1987

living cell technologies ltd (LHI) Top Compensated Officers

Co-Founder, Director of Clinical Research & I...
Total Annual Compensation: A$126.6K
Head of Finance & Administration
Total Annual Compensation: A$184.0K
Chief Executive
Total Annual Compensation: A$79.7K
Acting Chief Science & Medical Officer
Total Annual Compensation: A$245.9K
Compensation as of Fiscal Year 2014.

living cell technologies ltd (LHI) Key Developments

Living Cell Technologies Limited Announces Audited Consolidated and Parent Audited Earnings Results for the Full Year Ended June 30, 2014

Living Cell Technologies Limited announced audited consolidated and parent audited earnings results for the full year ended June 30, 2014. For the year on consolidated basis, the company reported total revenue and other income of AUD 7,941,227 against AUD 7,901,351 a year ago. Operating loss was AUD 1,041,332 against AUD 835,858 a year ago. Loss before income tax was AUD 6,778,896 against AUD 2,978,709 a year ago. Loss after income tax from continuing operations was AUD 6,778,896 against AUD 2,978,709 a year ago. Loss attributable to members of the parent entity was AUD 6,778,896 against AUD 2,978,709 a year ago. Loss per diluted share was 1.9 cents against earnings per diluted share of 0.6 cents a year ago. Net cash used in operating activities was AUD 82,441 against net cash provided by operating activities of AUD 1,336,934 a year ago. Purchase of property, plant and equipment were AUD 2,090 against AUD 19,530,000 a year ago. The increased loss was due to the prior year including a AUD 3 million option fee from Otsuka Pharmaceutical Factory Inc. and an increase in the share of the joint venture loss. On parent basis for the year, the company reported loss after income tax of AUD 6,734,858 against net profit of AUD 3,057,225 a year ago.

Living Cell Technologies Limited Appoints Dr. Ken Taylor as Chief Executive

Living Cell Technologies Limited announced that Dr. Ken Taylor has been appointed Chief Executive. Ken was appointed NTCELL Program Director in February and became Acting Chief Executive in April. Prior to joining LCT, Dr. Taylor was CEO of Antipodean Pharmaceuticals where he managed the Phase I and II studies of its lead compound in Parkinson's disease.

Otsuka Pharmaceutical Factory, Inc. Decides Not to Exercise Option to Acquire Rights to Develop NTCELL and Living Cell Technologies Limited to Develop NTCELL Independently

Living Cell Technologies Limited announced that Otsuka Pharmaceutical Factory Inc. (OPF) has decided not to exercise its option to acquire the rights to develop NTCELL through Diatranz Otsuka Limited (DOL). Consequently LCT will not receive the $2 million second instalment of the option fee. In line with the restructuring announced on 1 April 2014, the 50:50 joint venture company DOL will continue to focus on developing DIABECELL. This means that LCT retains all intellectual property for therapeutic use of NTCELL in Parkinson's and other neurological diseases. It will continue the regulatory process to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL in Parkinson's disease. LCT is forecasting to have sufficient funds to complete the trial.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LHI:GR €0.03 EUR +0.002

LHI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LHI.
View Industry Companies

Industry Analysis


Industry Average

Valuation LHI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIVING CELL TECHNOLOGIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at